Nuvectis Pharma reported a net loss of $6.1 million for Q1 2026, slightly higher than the previous year, while continuing patient enrollment in its NXP900 Phase 1b clinical trial for cancer treatment. The company highlighted promising preclinical data showing synergy of NXP900 combined with sotorasib in lung cancer models. With $25.1 million in cash, Nuvectis expects preliminary clinical data this summer and remains focused on advancing its oncology drug development with financial discipline.
Fury Gold Mines has restarted exploration and drilling activities at its Eau Claire project in Northern Quebec following a temporary halt due to a nearby wildfire. All personnel have safely returned, and operations resumed after confirming safe condi...
YieldMax announced weekly distributions for three of its Performance & Distribution Target 25 ETFs: MSST, NVIT, and TEST. Each ETF targets a 25% annual income level, with distributions scheduled for July 29, 2026. These ETFs use a call writing strate...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Dimensional Fund Advisors Ltd. has disclosed ownership of 11,780,819 shares, representing a 1.26% stake in Prologis Inc as of July 24, 2026. This disclosure is made under the Takeover Code, indicating a significant investment position. The firm also ...
Man Group PLC has publicly disclosed holding a 1.63% interest in Senior Plc through cash-settled equity swaps as of July 24, 2026. This disclosure is made under Rule 8.3 of the UK Takeover Code, indicating a significant stake in the company. The posi...
